$103.00
Value $179B
ABT and ALEC stock compared: price, dividend, valuation and results, from SEC filings.
$103.00
Value $179B
$2.33
Value $348M
Abbott Laboratories (ABT) has a market value of $179B and Alector (ALEC) $348M. Over the last year, with dividends, ABT moved -16.3% and ALEC +91.8%. The P/E is 38.1 for ABT and 8.4 for ALEC. Dividend yield: ABT 2.45%, ALEC none.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
ABT$179B
ALEC$348M
ABT is 515 times ALEC
Revenue, 12 months
ABT$48.2B
ALEC$173M
ABT is 278 times ALEC
Net income, 12 months
ABT$4.7B
ALEC$41M
ABT is 114 times ALEC
Operating margin
ABT13.8%
ALEC20.2%
6.4 points apart
ROIC
ABT6.3%
ALEC56.5%
50.2 points apart
P/E
ABT38.1
ALEC8.4
ABT is 4.5 times ALEC
Dividend yield
ABT2.5%
ALEC0.0%
2.5 points apart
5-year return
ABT-10.3%
ALEC-89.1%
78.8 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
ABT-10.3%
ALEC-89.1%
| Period | ABTWith dividends | ALECWith dividends |
|---|---|---|
| 1 year since November 19, 2025 | -16.3%Price -18.4% | +91.8%Price +91.8% |
| 3 years since November 20, 2023 | +8.4%+2.7% a yearPrice +1.8% | -52.4%-21.9% a yearPrice -52.4% |
| 5 years since November 19, 2021 | -10.3%-2.1% a yearPrice -18.8% | -89.1%-35.8% a yearPrice -89.1% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
ABTAbbott LaboratoriesALECAlector
| Price | $103.00 | $2.33 |
|---|---|---|
| Market value | $179B | $348M |
| Enterprise value (EV) | $206B | $209M |
| P/E | 38.1 | 8.4 |
| P/E, 5-year median | 33.7 | – |
| P/B | 3.5 | 3.0 |
| EV/EBIT | 31.0 | 6.0 |
| Free cash flow yield | 3.8% | – |
| Revenue, 12 months | $48.2B | $173M |
|---|---|---|
| Net income, 12 months | $4.7B | $41M |
| Free cash flow, 12 months | $6.8B | -$150M |
| Earnings per share, 12 months | $2.69 | $0.28 |
| Revenue growth, year on year | 5.7% | -79.1% |
| Revenue growth a year, past | +5.1%over 5 years | -0.1%over 5 years |
| EPS growth a year, past | +8.3%over 5 years | – |
| Gross margin | 56.9% | – |
|---|---|---|
| Operating margin | 13.8% | 20.2% |
| Net margin | 9.8% | 23.9% |
| ROIC | 6.3% | 56.5% |
| ROE | 9.1% | 100.8% |
| Cash | $4.3B | $139M |
|---|---|---|
| Total debt | $31.2B | $21M |
| Net debt / EBITDA | 3.3 | -3.4 |
| Interest cover | 6.7× | – |
| Dividend yield | 2.5% | – |
|---|---|---|
| Dividend per share, 12 months | $2.52 | – |
| Dividend growth a year, past | +10.4%over 5 years | – |
| Buyback yield | 0.5% | – |
| Shareholder yield | 2.9% | – |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Abbott Laboratories ($179B) is about 514.9 times Alector ($348M), at today's prices.
Since November 19, 2021, ABT's price moved -18.8% and ALEC's -89.1%. With dividends: ABT -10.3% (-2.1% a year), ALEC -89.1% (-35.8% a year). Past returns do not predict future ones.
The dividend yield at today's price is 2.45% for Abbott Laboratories and none for Alector. Over the last twelve months they paid $2.52 and – per share.
At today's price, the P/E is 38.1 for ABT and 8.4 for ALEC. It is the share price over the last twelve months' earnings per share.
Over the last twelve months, the net margin was 9.8% for Abbott Laboratories and 23.9% for Alector, and the operating margin 13.8% and 20.2%. Revenue was $48.2B and $173M.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.